Salutaris Medical Devices (SalutarisMD) is a clinical-stage radiotherapeutic company founded with the mission to develop innovative treatments for eye diseases, particularly those resistant to conventional therapies. The company's core vision is to improve the quality of life for millions suffering from advanced age-related macular degeneration (wet-AMD) and other related conditions. SalutarisMD offers a groundbreaking treatment aimed at addressing anti-VEGF resistant wet-AMD, providing an alternative to the current standard of frequent, lifelong injections.

Notable figures affiliated with SalutarisMD include a distinguished team of medical experts and a board of directors with extensive experience in ophthalmology and radiotherapy. The company has achieved significant milestones in its clinical trials, demonstrating the efficacy and safety of its radiotherapeutic approach. SalutarisMD's impact lies in its potential to revolutionize the treatment landscape for wet-AMD, offering hope to millions of patients worldwide who suffer from vision loss due to this condition.